History of the development of azole derivatives
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Until the 1940s, relatively few agents were available for the treatment of systemic fungal infections. The development of the polyene antifungals represented a major advance in medical mycology. Although amphotericin B quickly became the mainstay of therapy for serious infections, its use was associated with infusion-related side-effects and dose-limiting nephrotoxicity. The continued search for new and less toxic antifungals led to the discovery of the azoles several decades later. Ketoconazole, the first available compound for the oral treatment of systemic fungal infections, was released in the early 1980s. For almost a decade, ketoconazole was regarded as the drug of choice in nonlife-threatening endemic mycoses. The introduction of the first-generation triazoles represented a second major advance in the treatment of fungal infections. Both fluconazole and itraconazole displayed a broader spectrum of antifungal activity than the imidazoles and had a markedly improved safety profile compared with amphotericin B and ketoconazole. Despite widespread use, however, these agents became subject to a number of clinically important limitations related to their suboptimal spectrum of activity, the development of resistance, the induction of hazardous drug-drug interactions, their less than optimal pharmacokinetic profile (itraconazole capsules), and toxicity. In order to overcome these limitations, several analogues have been developed. These so-called 'second-generation' triazoles, including voriconazole, posaconazole and ravuconazole, have greater potency and possess increased activity against resistant and emerging pathogens, in particular against Aspergillus spp. If the toxicity profile of these agents is comparable to or better than that of the first-generation triazoles and drug interactions remain manageable, then these compounds represent a true expansion of our antifungal arsenal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880 · cited 1×
“…National Nosocomial Infection Surveillance Program from the Centers for Disease Control and Prevention (CDC) and the Surveillance and Control of Pathogens of Epidemiological Importance (SCOPE) study, Candida species now account for 7–8 % of all nosocomial bloodstream infections in the USA [38,39].”
BackgroundResistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 1×
“In addition, it is critical to recognize the concept of dose dependency in azole-susceptibility when approaching the therapy of these infections [49].”
BackgroundInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791 · cited 1×
“Unfortunately, the attributable mortality rate of (systemic) fungal infections remains high [8,9].”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Epidemiology of nosocomial fungal infections
Fridkin, S. K., & Jarvis, W. R. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.499 · Cited by 782
Trends in the postmortem epidemiology of invasive fungal infections at a University Hospital
Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G., & Huebner, K. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)92700-0 · Cited by 778
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755 · cited 1×
“Although the cause of this changing spectrum is multifactorial and has not been evaluated systematically, the selective pressure resulting from the widespread use of fluconazole has most probably contributed to the higher proportion of non-albicans species [40].”
BackgroundViscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 2×
“Unfortunately, the attributable mortality rate of (systemic) fungal infections remains high [8,9].”
BackgroundOral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542 · cited 1×
“…links between spectral changes and prior use of fluconazole have not yet been firmly proved; additional factors such as institu-tion-related differences in anti-infective protocols and treatment-specific factors may be equally important for fungal colonisation and subsequent infection [41].”
BackgroundItraconazole resistance in Aspergillus fumigatus
Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A., Warnock, D. W., & Kelly, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1364 · Cited by 508
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
Ketoconazole Blocks Adrenal Steroid Synthesis
PONT, A., WILLIAMS, P. L., LOOSE, D. S., FELDMAN, D., REITZ, R. E., BOCHRA, C., & STEVENS, D. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-370 · Cited by 422
Overview of medically important antifungal azole derivatives
Fromtling, R. A. (1988) · Clinical Microbiology Reviews · doi:10.1128/cmr.1.2.187 · Cited by 398
Hepatic Injury Associated With Ketoconazole Therapy
Lewis, J. H., Zimmerman, H. J., Benson, G. D., & Ishak, K. G. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80021-9 · Cited by 394
Fungal Infections in Solid-Organ Transplantation
Paya, C. V. (1993) · Clinical Infectious Diseases · doi:10.1093/clind/16.5.677 · Cited by 378
Humphrey, M. J., Jevons, S., & Tarbit, M. H. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.5.648 · Cited by 365
Heeres, J., Backx, L. J. J., Mostmans, J. H., & Van Cutsem, J. (1979) · Journal of Medicinal Chemistry · doi:10.1021/jm00194a023 · Cited by 343
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
SOME BIOLOGICAL EFFECTS PRODUCED BY BENZIMIDAZOLE AND THEIR REVERSAL BY PURINES
Woolley, D. W. (1944) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)72045-0 · Cited by 247
Emerging Fungal Pathogens in Immunocompromised Patients: Classification, Diagnosis, and Management
Vartivarian, S. E., Anaissie, E. J., & Bodey, G. P. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.supplement_2.s487 · Cited by 240
The New Fungal Opportunists Are Coming
Perfect, J. R., & Schell, W. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s112 · Cited by 224
Recovery of the Immune System With Antiretroviral Therapy: The End of Opportunism?
Powderly, W. G., Landay, A., & Lederman, M. M. (1998) · JAMA · doi:10.1001/jama.280.1.72 · Cited by 221
Disposition of ketoconazole, an oral antifungal, in humans
Brass, C., Galgiani, J. N., Blaschke, T. F., Defelice, R., O'Reilly, R. A., & Stevens, D. A. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.1.151 · Cited by 210
Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 208
Voriconazole: A New Triazole Antifungal
Sabo, J., & Abdel‐Rahman, S. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19237 · Cited by 199
Fungal infections: a growing threat.
Dixon, D. M., McNeil, M. M., Cohen, M. L., Gellin, B. G., & Montagne, J. R. L. (1996) · PubMed · Cited by 193
Arndt, C. A. S., Walsh, T. J., McCully, C. L., Balis, F. M., Pizzo, P. A., & Poplack, D. G. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.1.178 · Cited by 169
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES MYCOSES STUDY GROUP (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-6-861 · Cited by 157
The influence of gastric acidity on the bio-availability of ketoconazole
VAN DER MEER, J. W. M., KEUNING, J. J., SCHEIJGROND, H. W., HEYKANTS, J., VAN CUTSEM, J., & BRUGMANS, J. (1980) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/6.4.552 · Cited by 154
Jones, R. N., Marshall, S. A., Pfaller, M. A., Wilke, W. W., Hollis, R. J., Erwin, M. E., Edmond, M. B., & Wenzel, R. P. (1997) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00115-6 · Cited by 153
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
Glasmacher, A., Hahn, C., Leutner, C., Molitor, E., Wardelmann, E., Losem, C., Sauerbruch, T., Marklein, G., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00505.x · Cited by 147
Antifungal Agents. Part II. The Azoles
Terrell, C. L. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.1.78 · Cited by 130
In vitro studies with R 51,211 (itraconazole)
Espinel-Ingroff, A., Shadomy, S., & Gebhart, R. J. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.1.5 · Cited by 130
Mechanisms of Fungal Resistance: An Overview
Balkis, M. M., Leidich, S. D., Mukherjee, P. K., & Ghannoum, M. A. (2002) · Drugs · doi:10.2165/00003495-200262070-00004 · Cited by 130
Cartledge, J. D., Midgely, J., & Gazzard, B. G. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.477 · Cited by 126
New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer
Chiou, C. C., Groll, A. H., & Walsh, T. J. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-120 · Cited by 124
Azole Cross-Resistance in Aspergillus fumigatus
Mosquera, J., & Denning, D. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.556-557.2002 · Cited by 121
Heel, R. C., Brogden, R. N., Pakes, G. E., Speight, T. M., & Avery, G. S. (1980) · Drugs · doi:10.2165/00003495-198019010-00002 · Cited by 117
Deep Infections From Petriellidium boydii Treated With Miconazole
Lutwick, L. I. (1979) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1979.03290290040023 · Cited by 100
Cytochrome p‐450: Target for itraconazole
Vanden Bossche, H., Bellens, D., Cools, W., Gorrens, J., Marichal, P., Verhoeven, H., Willemsens, G., De Coster, R., Beerens, D., Haelterman, C., et al. (1986) · Drug Development Research · doi:10.1002/ddr.430080133 · Cited by 97
Ketoconazole therapy of progressive coccidioidomycosis
Galgiani, J. N., Stevens, D. A., Graybill, J. R., Dismukes, W. E., & Cloud, G. A. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90143-x · Cited by 92
FUNGAL INFECTIONS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME
Minamoto, G. Y., & Rosenberg, A. S. (1997) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70523-x · Cited by 91
Potoski, B. A., & Brown, J. (2002) · Clinical Infectious Diseases · doi:10.1086/343746 · Cited by 87
Sobel, J. D., Ohmit, S. E., Schuman, P., Klein, R. S., Mayer, K., Duerr, A., Vazquez, J. A., Rompalo, A., & HIV Epidemiology Research Study (HERS) Group (2001) · The Journal of Infectious Diseases · doi:10.1086/317936 · Cited by 83
Drouhet, E., & Dupont, B. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.4.606 · Cited by 82
In Vitro Antifungal Activity of Clotrimazole (Bay b 5097)
Shadomy, S. (1971) · Infection and Immunity · doi:10.1128/iai.4.2.143-148.1971 · Cited by 77
Review Article Cytochromes P450 in fungi
BOSSCHE, H. V., & Koymans, L. M. H. (1998) · Mycoses · doi:10.1111/j.1439-0507.1998.tb00581.x · Cited by 76
Treatment of paracoccidioidomycosis with ketoconazole: A three-year experience
Angela Restrepo, M., Gómez, I., Cano, L. E., Arango, M. D., Gutiérrez, F., Sanín, A., & Robledo, M. A. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90513-2 · Cited by 76
Prentice, A. G., Warnock, D. W., Johnson, S. A. N., Taylor, P. C., & Oliver, D. A. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.4.657 · Cited by 74
Boogaerts, M., Maertens, J. A., van der Geest, R., Bosly, A., Michaux, J., Hoof, A. V., Cleeren, M., Woestenborghs, R. J. H., & Beule, K. D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.981-985.2001 · Cited by 72
Self-citationFungal Cell Wall Inhibitors: Emphasis on Clinical Aspects
Maertens, J. A., & Boogaerts, M. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003401299 · Cited by 60
Self-citationClinical Experience with Itraconazole in Systemic Fungal Infections
Boogaerts, M., & Maertens, J. A. (2001) · Drugs · doi:10.2165/00003495-200161001-00004 · Cited by 54
Self-citationFailure of Ketoconazole in Cryptococcal Meningitis
Perfect, J. R., Durack, D. T., Hamilton, J. D., & Gallis, H. A. (1982) · JAMA · doi:10.1001/jama.1982.03320490047035 · Cited by 49
Miconazole in Cryptococcosis and Systemic Candidiasis: A Word of Caution
Bennett, J. E., & Remington, J. S. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-5-708 · Cited by 37
Michallet, M., Persat, F., Kranzhöfer, N., Levron, J.-C., Prat, C., Belhabri, A., Chwetzoff, E., Le Moing, J.-P., Fiere, D., & Piens, M.-A. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701270 · Cited by 31
Cited by
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Metadata
- Authors
- Maertens, J. A.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2004
- Volume
- 10
- Pages
- 1-10
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W1755623111
- Cited by
- 475
- References
- 63
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.